Supernus Resubmits NDA to FDA for Apomorphine Infusion Device to Treat Parkinson's
October 09 2023 - 4:45PM
Dow Jones News
By Stephen Nakrosis
Supernus Pharmaceuticals resubmitted a new drug application to
the Food and Drug Administration for its apomorphine infusion
device to treat patients with Parkinson's disease.
The SPN-830 apomorphine infusion device is designed for the
continuous treatment of motor fluctuations in Parkinson's
disease.
In October 2022, Supernus said it received a complete response
letter from the FDA indicating the company's NDA wouldn't be
approved in its then-current form. At the time, Supernus said the
FDA was seeking additional information and analysis, but didn't
request additional efficacy or clinical studies.
The company also said "the FDA mentioned at the time that
approval of the NDA required inspections that could not be
completed in a timely manner due to Covid-19 travel
restrictions."
Supernus said it believes it addressed the FDA's questions
related to the complete response letter and will continue to work
with the agency as it reviews the SPN-830 NDA.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 09, 2023 17:30 ET (21:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From May 2024 to Jun 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Jun 2023 to Jun 2024